Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing
medication and identify the dose or doses that may effectively reduce axillary sweating in
hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.